Small Animal Model Systems for Studying Hepatitis B Virus Replication and Pathogenesis

 

 Buy Article Permissions and Reprints

ABSTRACT

The lack of reliable in vitro infection systems and convenient animal models has hindered progress in hepatitis B virus (HBV) research and the development of new treatment options. Due to various restraints encountered using chimpanzees and other models of HBV infection that are based on HBV-related viruses, and due to the necessity to work with small and well-characterized animal systems, it is not surprising that most recent developments have focused on mice. Various strains of transgenic mice harboring the entire HBV genome, or selected viral genes, were developed and proved to be very useful to elucidate mechanisms of HBV replication and pathogenesis. Furthermore, novel, exciting alternative mouse models have been developed recently, which allow not only studies on viral replication, but also the investigation of mechanisms of viral entry and clearance. This article provides an overview and discussion of the different mouse models of HBV replication and infection that are currently available.

REFERENCES

• 1 Chen M, Sallberg M, Hughes J et al.. Immune tolerance split between hepatitis B virus precore and core proteins.  J Virol. 2005;  79 3016-3027
  CrossrefPubMedGoogle Scholar
• 2 Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.  Gastroenterology. 2004;  127(suppl 1) S56-S61
  CrossrefPubMedGoogle Scholar
• 3 Bruns M, Miska S, Chassot S, Will H. Enhancement of hepatitis B virus infection by noninfectious subviral particles.  J Virol. 1998;  72 1462-1468
  PubMedGoogle Scholar
• 4 Sells M A, Chen M L, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.  Proc Natl Acad Sci U S A. 1987;  84 1005-1009
  PubMedGoogle Scholar
• 5 Galle P R, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H. In vitro experimental infection of primary human hepatocytes with hepatitis B virus.  Gastroenterology. 1994;  106 664-673
  CrossrefPubMedGoogle Scholar
• 6 Gripon P, Diot C, Guguen-Guillouzo C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration.  Virology. 1993;  192 534-540
  CrossrefPubMedGoogle Scholar
• 7 Gripon P, Diot C, Theze N et al.. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide.  J Virol. 1988;  62 4136-4143
  CrossrefPubMedGoogle Scholar
• 8 Schulze-Bergkamen H, Untergasser A, Dax A et al.. Primary human hepatocytes-a valuable tool for investigation of apoptosis and hepatitis B virus infection.  J Hepatol. 2003;  38 736-744
  CrossrefPubMedGoogle Scholar
• 9 Gripon P, Rumin S, Urban S et al.. Infection of a human hepatoma cell line by hepatitis B virus.  Proc Natl Acad Sci U S A. 2002;  99 15655-15660
  CrossrefPubMedGoogle Scholar
• 10 Jaeschke H. Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity?.  Hepatology. 2003;  38 1053-1055
  PubMedGoogle Scholar
• 11 Barker L F, Chisari F V, McGrath P P et al.. Transmission of type B viral hepatitis to chimpanzees.  J Infect Dis. 1973;  127 648-662
  PubMedGoogle Scholar
• 12 Bertoni R, Sette A, Sidney J et al.. Human class I supertypes and CTL repertoires extend to chimpanzees.  J Immunol. 1998;  161 4447-4455
  PubMedGoogle Scholar
• 13 Will H, Cattaneo R, Koch H G et al.. Cloned HBV DNA causes hepatitis in chimpanzees.  Nature. 1982;  299 740-742
  PubMedGoogle Scholar
• 14 Berthelot P, Courouce A M, Eyquem A et al.. Hepatitis B vaccine safety monitoring in the chimpanzee: interpretation of results.  J Med Primatol. 1984;  13 119-133
  PubMedGoogle Scholar
• 15 Ohmura T, Ohmizu A, Sumi A et al.. Properties of recombinant hepatitis B vaccine.  Biochem Biophys Res Commun. 1987;  149 1172-1178
  CrossrefPubMedGoogle Scholar
• 16 Fujisawa Y, Kuroda S, Van Eerd P M, Schellekens H, Kakinuma A. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre- S2 + S) protein particles (a third generation vaccine).  Vaccine. 1990;  8 192-198
  CrossrefPubMedGoogle Scholar
• 17 Ogata N, Cote P J, Zanetti A R et al.. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus.  Hepatology. 1999;  30 779-786
  CrossrefPubMedGoogle Scholar
• 18 Baumert T F, Yang C, Schurmann P et al.. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes.  Hepatology. 2005;  41 247-256
  CrossrefPubMedGoogle Scholar
• 19 von Weizsacker F, Kock J, MacNelly S, Ren S, Blum H E, Nassal M. The tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary tupaia hepatocytes.  Methods Mol Med. 2004;  96 153-161
  PubMedGoogle Scholar
• 20 Lin E, Luscombe C, Colledge D, Wang Y Y, Locarnini S. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.  Antimicrob Agents Chemother. 1998;  42 2132-2137
  PubMedGoogle Scholar
• 21 Nicoll A J, Colledge D L, Toole J J, Angus P W, Smallwood R A, Locarnini S A. Inhibition of duck hepatitis B virus replication by 9-(2- phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.  Antimicrob Agents Chemother. 1998;  42 3130-3135
  PubMedGoogle Scholar
• 22 Korba B E, Cote P J, Menne S et al.. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection.  Antivir Ther. 2004;  9 937-952
  PubMedGoogle Scholar
• 23 Foster W K, Miller D S, Scougall C A, Kotlarski I, Colonno R J, Jilbert A R. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.  J Virol. 2005;  79 5819-5832
  CrossrefPubMedGoogle Scholar
• 24 Summers J, Mason W S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate.  Cell. 1982;  29 403-415
  CrossrefPubMedGoogle Scholar
• 25 Chen H S, Kaneko S, Girones R et al.. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks.  J Virol. 1993;  67 1218-1226
  PubMedGoogle Scholar
• 26 Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo.  J Virol. 1994;  68 2026-2030
  PubMedGoogle Scholar
• 27 Dandri M, Schirmacher P, Rogler C E. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication.  J Virol. 1996;  70 5246-5254
  PubMedGoogle Scholar
• 28 Summers J, Jilbert A R, Yang W et al.. Hepatocyte turnover during resolution of a transient hepadnaviral infection.  Proc Natl Acad Sci U S A. 2003;  100 11652-11659
  CrossrefPubMedGoogle Scholar
• 29 Summers J, Mason W S. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.  Proc Natl Acad Sci U S A. 2004;  101 638-640
  CrossrefPubMedGoogle Scholar
• 30 Mason W S, Jilbert A R, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection.  Proc Natl Acad Sci U S A. 2005;  102 1139-1144
  CrossrefPubMedGoogle Scholar
• 31 Chisari F V, Pinkert C A, Milich D R et al.. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state.  Science. 1985;  230 1157-1160
  PubMedGoogle Scholar
• 32 Araki K, Miyazaki J, Hino O et al.. Expression and replication of hepatitis B virus genome in transgenic mice.  Proc Natl Acad Sci U S A. 1989;  86 207-211
  PubMedGoogle Scholar
• 33 Kim C M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice.  Nature. 1991;  351 317-320
  CrossrefPubMedGoogle Scholar
• 34 Guidotti L G, Matzke B, Schaller H, Chisari F V. High-level hepatitis B virus replication in transgenic mice.  J Virol. 1995;  69 6158-6169
  PubMedGoogle Scholar
• 35 Guidotti L G, Rochford R, Chung J, Shapiro M, Purcell R, Chisari F V. Viral clearance without destruction of infected cells during acute HBV infection.  Science. 1999;  284 825-829
  CrossrefPubMedGoogle Scholar
• 36 Julander J G, Colonno R J, Sidwell R W, Morrey J D. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus.  Antiviral Res. 2003;  59 155-161
  CrossrefPubMedGoogle Scholar
• 37 Julander J G, Sidwell R W, Morrey J D. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus.  Antiviral Res. 2002;  55 27-40
  CrossrefPubMedGoogle Scholar
• 38 Weber O, Schlemmer K H, Hartmann E et al.. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.  Antiviral Res. 2002;  54 69-78
  CrossrefPubMedGoogle Scholar
• 39 Kimura K, Kakimi K, Wieland S, Guidotti L G, Chisari F V. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice.  J Virol. 2002;  76 10702-10707
  CrossrefPubMedGoogle Scholar
• 40 Kakimi K, Lane T E, Wieland S et al.. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.  J Exp Med. 2001;  194 1755-1766
  CrossrefPubMedGoogle Scholar
• 41 Uprichard S L, Boyd B, Althage A, Chisari F V. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.  Proc Natl Acad Sci U S A. 2005;  102 773-778
  CrossrefPubMedGoogle Scholar
• 42 Chang J, Taylor J M. Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action.  J Virol. 2003;  77 9728-9731
  CrossrefPubMedGoogle Scholar
• 43 Shlomai A, Shaul Y. RNA interference: small RNAs effectively fight viral hepatitis.  Liver Int. 2004;  24 526-531
  CrossrefPubMedGoogle Scholar
• 44 Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference.  Hepatology. 2003;  37 764-770
  CrossrefPubMedGoogle Scholar
• 45 Moriyama T, Guilhot S, Klopchin K et al.. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice.  Science. 1990;  248 361-364
  PubMedGoogle Scholar
• 46 Guidotti L G, Guilhot S, Chisari F V. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways.  J Virol. 1994;  68 1265-1270
  PubMedGoogle Scholar
• 47 Guidotti L G, Matzke B, Pasquinelli C, Schoenberger J M, Rogler C E, Chisari F V. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice.  J Virol. 1996;  70 7056-7061
  PubMedGoogle Scholar
• 48 Guidotti L G, Ishikawa T, Hobbs M V, Matzke B, Schreiber R, Chisari F V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.  Immunity. 1996;  4 25-36
  CrossrefPubMedGoogle Scholar
• 49 Heise T, Guidotti L G, Cavanaugh V J, Chisari F V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice.  J Virol. 1999;  73 474-481
  PubMedGoogle Scholar
• 50 Wieland S F, Vega R G, Muller R et al.. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes.  J Virol. 2003;  77 1227-1236
  PubMedGoogle Scholar
• 51 Sitia G, Isogawa M, Iannacone M, Campbell I L, Chisari F V, Guidotti L G. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs.  J Clin Invest. 2004;  113 1158-1167
  CrossrefPubMedGoogle Scholar
• 52 Larkin J, Clayton M, Sun B et al.. Hepatitis B virus transgenic mouse model of chronic liver disease.  Nat Med. 1999;  5 907-912
  PubMedGoogle Scholar
• 53 Baron J L, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection.  Immunity. 2002;  16 583-594
  CrossrefPubMedGoogle Scholar
• 54 Petersen J, Dandri M, Burkle A, Zhang L, Rogler C E. Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.  J Virol. 1997;  71 5455-5463
  PubMedGoogle Scholar
• 55 Dandri M, Burda M R, Burkle A et al.. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation.  Hepatology. 2002;  35 217-223
  CrossrefPubMedGoogle Scholar
• 56 Chisari F V, Filippi P, McLachlan A et al.. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice.  J Virol. 1986;  60 880-887
  PubMedGoogle Scholar
• 57 Chisari F V, Filippi P, Buras J et al.. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice.  Proc Natl Acad Sci U S A. 1987;  84 6909-6913
  PubMedGoogle Scholar
• 58 Bouchard M J, Schneider R J. The enigmatic X gene of hepatitis B virus.  J Virol. 2004;  78 12725-12734
  CrossrefPubMedGoogle Scholar
• 59 Slagle B L, Lee T H, Medina D, Finegold M J, Butel J S. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene.  Mol Carcinog. 1996;  15 261-269
  CrossrefPubMedGoogle Scholar
• 60 Koike K, Moriya K, Iino S et al.. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice.  Hepatology. 1994;  19 810-819
  CrossrefPubMedGoogle Scholar
• 61 Ueda H, Ullrich S J, Gangemi J D et al.. Functional inactivation but not structural mutation of p53 causes liver cancer.  Nat Genet. 1995;  9 41-47
  CrossrefPubMedGoogle Scholar
• 62 Delaney W E, Isom H C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus.  Hepatology. 1998;  28 1134-1146
  CrossrefPubMedGoogle Scholar
• 63 Sprinzl M F, Oberwinkler H, Schaller H, Protzer U. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier.  J Virol. 2001;  75 5108-5118
  CrossrefPubMedGoogle Scholar
• 64 Ren S, Nassal M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors.  J Virol. 2001;  75 1104-1116
  CrossrefPubMedGoogle Scholar
• 65 Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M. Efficient gene transfer into human hepatocytes by baculovirus vectors.  Proc Natl Acad Sci U S A. 1995;  92 10099-10103
  PubMedGoogle Scholar
• 66 Hofmann C, Strauss M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system.  Gene Ther. 1998;  5 531-536
  CrossrefPubMedGoogle Scholar
• 67 Isogawa M, Kakimi K, Kamamoto H, Protzer U, Chisari F V. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen.  Virology. 2005;  333 293-300
  CrossrefPubMedGoogle Scholar
• 68 Feitelson M A, DeTolla L J, Zhou X D. A chronic carrierlike state is established in nude mice injected with cloned hepatitis B virus DNA.  J Virol. 1988;  62 1408-1415
  PubMedGoogle Scholar
• 69 Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.  Gene Ther. 1999;  6 1258-1266
  CrossrefPubMedGoogle Scholar
• 70 Yang P L, Althage A, Chung J, Chisari F V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection.  Proc Natl Acad Sci U S A. 2002;  99 13825-13830
  CrossrefPubMedGoogle Scholar
• 71 Klein C, Bock C T, Wedemeyer H et al.. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.  Gastroenterology. 2003;  125 9-18
  CrossrefPubMedGoogle Scholar
• 72 McCaffrey A P, Nakai H, Pandey K et al.. Inhibition of hepatitis B virus in mice by RNA interference.  Nat Biotechnol. 2003;  21 639-644
  CrossrefPubMedGoogle Scholar
• 73 Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice.  Mol Ther. 2003;  8 769-776
  CrossrefPubMedGoogle Scholar
• 74 Morrissey D V, Lockridge J A, Shaw L et al.. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.  Nat Biotechnol. 2005;  23 1002-1007
  CrossrefPubMedGoogle Scholar
• 75 Ilan E, Burakova T, Dagan S et al.. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents.  Hepatology. 1999;  29 553-562
  CrossrefPubMedGoogle Scholar
• 76 Eren R, Ilan E, Nussbaum O et al.. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees.  Hepatology. 2000;  32 588-596
  CrossrefPubMedGoogle Scholar
• 77 Bocher W O, Galun E, Marcus H et al.. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse.  Hepatology. 2000;  31 480-487
  CrossrefPubMedGoogle Scholar
• 78 Bocher W O, Dekel B, Schwerin W et al.. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.  Eur J Immunol. 2001;  31 2071-2079
  CrossrefPubMedGoogle Scholar
• 79 Ohashi K, Marion P L, Nakai H et al.. Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses.  Nat Med. 2000;  6 327-331
  PubMedGoogle Scholar
• 80 Brown J J, Parashar B, Moshage H et al.. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice.  Hepatology. 2000;  31 173-181
  CrossrefPubMedGoogle Scholar
• 81 Gupta S, Bhargava K K, Novikoff P M. Mechanisms of cell engraftment during liver repopulation with hepatocyte transplantation.  Semin Liver Dis. 1999;  19 15-26
  PubMedGoogle Scholar
• 82 Sandgren E P, Palmiter R D, Heckel J L, Daugherty C C, Brinster R L, Degen J L. Complete hepatic regeneration after somatic deletion of an albumin- plasminogen activator transgene.  Cell. 1991;  66 245-256
  CrossrefPubMedGoogle Scholar
• 83 Rhim J A, Sandgren E P, Degen J L, Palmiter R D, Brinster R L. Replacement of diseased mouse liver by hepatic cell transplantation.  Science. 1994;  263 1149-1152
  CrossrefPubMedGoogle Scholar
• 84 Overturf K, Al-Dhalimy M, Tanguay R et al.. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.  Nat Genet. 1996;  12 266-273
  PubMedGoogle Scholar
• 85 Mignon A, Guidotti J E, Mitchell C et al.. Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes.  Nat Med. 1998;  4 1185-1188
  PubMedGoogle Scholar
• 86 Shinkai Y, Rathbun G, Lam K P et al.. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.  Cell. 1992;  68 855-867
  CrossrefPubMedGoogle Scholar
• 87 Petersen J, Dandri M, Gupta S, Rogler C E. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma.  Proc Natl Acad Sci U S A. 1998;  95 310-315
  PubMedGoogle Scholar
• 88 Dandri M, Burda M R, Torok E et al.. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus.  Hepatology. 2001;  33 981-988
  CrossrefPubMedGoogle Scholar
• 89 Meuleman P, Libbrecht L, De Vos R et al.. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.  Hepatology. 2005;  41 847-856
  CrossrefPubMedGoogle Scholar
• 90 Mercer D F, Schiller D E, Elliott J F et al.. Hepatitis C virus replication in mice with chimeric human livers.  Nat Med. 2001;  7 927-933
  CrossrefPubMedGoogle Scholar
• 91 Tateno C, Yoshizane Y, Saito N et al.. Near completely humanized liver in mice shows human-type metabolic responses to drugs.  Am J Pathol. 2004;  165 901-912
  CrossrefPubMedGoogle Scholar
• 92 Tsuge M, Hiraga N, Takaishi H et al.. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus.  Hepatology. 2005;  42 1046-1054
  CrossrefPubMedGoogle Scholar
• 93 Dandri M, Burda M R, Zuckerman D M et al.. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.  J Hepatol. 2005;  42 54-60
  PubMedGoogle Scholar

Jörg PetersenM.D. 

I. Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg-Eppendorf, Martinistr

52, D-20246, Hamburg, Germany